AbCellera Biologics Inc. Common Shares (ABCL) Technical Analysis
$11.09
Insights
- AbCellera Biologics Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for AbCellera Biologics Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, AbCellera Biologics Inc. stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for AbCellera Biologics Inc. stock suggests that it is a good time to sell or bad time to initiate a fresh position
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 61.24 | Sell |
Stochastic | 46.73, 48.6 | Neutral |
Ultimate Oscillator | 59.24 | Neutral |
Stochastic Relative Strength Index | 3.73, 3.67 | Buy |
Moving Average Convergence Divergence | 0.96, 1.15 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 11.71 | Buy |
20 | 11.37 | Buy |
50 | 8.5 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 11.42 | Buy |
20 | 10.8 | Buy |
50 | 9.02 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 11.72 | Sell |
20 | 11.04 | Neutral |
50 | 8.8 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 11.73 | Sell |
20 | 12.18 | Buy |
50 | 11.22 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 11.36 | Sell |
20 | 12.17 | Buy |
50 | 12.13 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 11.83 |
Resistance L2 | 11.71 |
Resistance L1 | 11.57 |
Pivot Point | 11.45 |
Support L1 | 11.31 |
Support L2 | 11.19 |
Support L3 | 11.05 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.